ABSTRACT
Not too long ago type 2 diabetes was mostly considered a contraindication against renal replacement therapy (RRT). An impressive body of evidence has meanwhile accumulated upon which selection of therapeutic options in such patients can be based. Although diabetic patients, particularly type 2, continue to have a poorer outcome on RRT than non-diabetic patients, survival has become progressively better. Recent strategies to improve prognosis by appropriate timing of the start of treatment, by preventing cardiovascular complications in the predialytic stage, and by optimising glycemic control as well as lipid lowering are very promising indeed.
